MAPK/ERK pathway inhibitors as novel antiviral compounds

Currently we are studying MAPK kinase inhibitors as potential antiviral therapeutics. We studied the antiviral activity of six inhibitors of various kinases—cobimetinib, binimetinib, ravoxertinib, tomivosertib, MCP110, and BIX02189—against human influenza virus. We demonstrated that the MNK1/2 kinase inhibitor tomivosertib reduces the replication of influenza A and B viruses in competent MDCK cells at concentrations of 50 and 100 µM